Antifungal therapy in invasive fungal infections

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 522-530

  Chen, Sharon C A ^a   Playford, E Geoffrey ^b   Sorrell, Tania C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; DEFERASIROX; DEFERIPRONE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IRON CHELATING AGENT; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POLYENE; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA GLABRATA; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CLINICAL TRIAL; CRYPTOCOCCOSIS; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; FUSARIOSIS; FUSARIUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; INVASIVE MOULD INFECTION; KERATITIS; LUNG ASPERGILLOSIS; MENINGOENCEPHALITIS; MORTALITY; MUCORMYCOSIS; MYCOSIS; NEUROCRYPTOCOCCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; RECOMMENDED DRUG DOSE; REVIEW; SCEDOSPORIUM; SYSTEMIC MYCOSIS; UNSPECIFIED SIDE EFFECT; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; HUMANS; MYCOSES; PRACTICE GUIDELINES AS TOPIC; ZYGOMYCOSIS;

EID: 77956647847     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.06.002     Document Type: Review

References (81)

1. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., Pfaller M., Chang C., Webster K., Marr K. Epidemiology and outcome of invasive fungal infection in adult haematopoietic stem cell transplant recipients: analysis of multicentre Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
2. Ben-Ami R., Lewis R.E., Kontoyiannis D.P. Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Curr Opin Infect Dis 2009, 22:376-384.
3. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., Anaissie E.J., Brumble L.M., Herwaldt L., Ito J., et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis 2010, 50:1101-1111.
4. Pfaller M.A., Diekema D.J. Azole antifungal drug cross-resistance: mechanisms, epidemiology and clinical significance. J Invasive Fungal Infect 2007, 1:74-92.
5. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
6. The periodic health examination. Canadian task force on the periodic health examination. Can Med Assoc J 1979, 121:1193-1254.
7. Wheat L.J., Freifeld A., Kleiman M.B., Baddley J.W., McKinsey D.S., Loyd J.E., Kauffman C.A. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807-825.
8. Chapman S.W., Dismukes W.E., Proia L.A., Bradshaher R.W., Pappas P.G., Threikeld, Kauffman C.A. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801-1812.
9. Galgiani J.N., Ampel N.M., Blair J.E., Catanzaro A., Johnson R.H., Stevens D.A. Coccidioidomycosis. Clin Infect Dis 2005, 41:1217-1223.
10. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
11. Playford EG, Nimmo GR, Tilse M, Sorrell TC: The increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect 2010, in press: doi:10.1016/j.jhin.2010.01.022.
12. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29:978-980.
13. Arendrup M.C., Fuursted K., Gahrn-Hansen B., Schonheyder H.C., Knudsen J.D., Jensen I.M., Bruun B., Christensen J.J., Johansen H.K. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008, 14:487-494.
14. Marriott D., Playford E.G., Chen S., Slavin M., Nguyen Q., Ellis D., Sorrell T. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009, 13:R115. the Australian Candidaemia Study.
15. Bougnoux M.-E., Kac G., Aegerter P., d'Enfert C., Fagon J.-Y., CandiRea Study G Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Int Care Med 2008, 34:292-299.
16. Leroy O., Gangneux J.-P., Montravers P., Mira J.-P., Gouin F., Sollet J.-P., Carlet J., Reynes J., Rosenheim M., Regnier B., Lortholary O. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618. AmarCand Study Group.
17. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
18. Montravers P., Dupont H., Gauzit R., Veber B., Auboyer C., Blin P., Hennequin C., Martin C. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006, 34:646-652.
19. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., Bearden D.T. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31.
20. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., et al. Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
21. Thursky K.A., Playford E.G., Seymour J.F., Sorrell T.C., Ellis D.H., Guy S.D., Gilroy N., Chu J., Shaw D.R. Recommendations for the treatment of established fungal infections. Int Med J 2008, 38:496-520.
22. Playford E.G., Marriott D., Nguyen Q., Chen S., Ellis D., Slavin M., Sorell T.C. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36:2034-2039.
23. Lee I., Fishman N.O., Zaoutis T.E., Morales K.H., Weiner M.G., Synnestvedt M., Nachamkin I., Lautenbach E. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Int Med 2009, 169:379-383.
24. Tumbarello M., Posteraro B., Trecarichi E.M., Sanguinetti M. Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. Arch Int Med 2009, 169:1444-1445.
25. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., Betts R., Wible M., Goldstein B.P., Schranz J., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482.
26. Rodriguez-Tudela J.L., Almirante B., Rodriguez-Pardo D., Laguna F., Donnelly J.P., Mouton J.W., Pahissa A., Cuenca-Estrella M. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007, 51:3599-3604.
27. Pfaller M.A., Diekema D.J., Sheehan D.J. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. J Clin Microbiol 2006, 19:435-447.
28. Pai M.P., Turpin R.S., Garey K.W. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007, 51:35-39.
29. Baddley J.W., Patel M., Bhavnani S.M., Moser S.A., Andes D.R. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008, 52:3022-3028.
30. Hope W.W., Billaud E.M., Lestner J., Denning D.W. Therapeutic monitoring for triazoles. Curr Opin Infect Dis 2008, 21:580-586.
31. Pappas P.G., Rotstein C.M.F., Betts R.F., Nucci M., Talwar D., De Waele J.J., Vazquez J.A., Dupont B.F., Horn D.L., Ostrosky-Zeichner L., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893.
32. Betts R.F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R.J., Herbrecht R., Ruiz-Palacios G., Young J.-A.H., Baddley J.W., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676-1684.
33. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
34. Hage C.A., Wood K.L., Winer-Muram H.T., Wilson S.J., Sarosi G., Knox K.S. Pulmonary cryptococcosis after anti-tumour necrosis factor-alpha therapy. Chest 2003, 124:2395-2397.
35. Sun H.Y., Alexander B.D., Lortholary O., Dormer F., Forrestt G.N., Lyon G.M., Somani J., Gupta K.L., Busto R.D., Pruett T.L., et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009, 49:1721-1728.
36. MacDougall L., Kidd S., Galanis E., Mak S., Leslie M.J., Cielslak P.R., Kronstad J.W., Morshed M.G., Bartlett K.H. Spread of Cryptococcus gattii in British Columbia, Canada and its detection in the Pacific Northwest, USA. Emerg Infect Dis 2007, 13:42-50.
37. Bicanic T., Meintjes G., Wood R., Hayes M., Rebe K., Bekker L.G., Harrison T. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76-80.
38. Dromer F., Bernede-Bauduin C., Guillemot D., Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008, 3:e2870. French Cryptococcosis Study Group.
39. Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., Harrison T.S., Larsen R.A., Lortholary O., Nguyen M.-H., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322.
40. Melifchik E., Leal M.A., Haubrich R., Bozzette S.A., Tilles J.G., Leedom J.M., McCutchan J.A., Larsen R.A. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008, 46:393-395.
41. Singh N., Lortholary O., Alexander B.D., Gupta K.L., John G.T., Pursell K.J., Munoz P., Klintmalm G.B., Stosor V., Del Busto R., et al. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection. Transplantation 2005, 80:1033-1039.
42. Singh N., Perfect J.R. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007, 7:395-401.
43. Garcia-Vidal C., Upton A., Kirby K.A., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47:1041-1050.
44. Pyrgos V., Shoham S., Walsh T.J. Pulmonary zygomycosis. Semin Respir Crit Care 2008, 29:111-120.
45. Baddley J.W., Marr K.A., Andes D.R., Walsh T.J., Kauffman C.A., Kontoyiannis D.P., Ito J.I., Balajee S.A., Pappas P.G., Moser S.A. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the transplant-associated infection surveillance network. J Clin Microbiol 2009, 47:3271-3275.
46. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C., Pasqualotto A.C., Laverdiere M., Arendrup M., Perlin D.S., Denning D.W. Frequency and evolution of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2009, 15:1068-1076.
47. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyianns D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
48. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.-W., Kern W.V., Marr K.A., Ribaud P., Lortholary O., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
49. Cornerly O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., Heussel C., Lortholary O., Rieger C., Boehme A., et al. Liposomal amphotericin B as initial therapy for invasive mould infections: a randomised trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
50. Viscoli C., Herbrecht R., Akan H., Baila L., Sonet A., Galamini A., Giagounidis A., Marchetti O., Martino R., Meert L., et al. An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in hematological patients. J Antimicrob Chemother 2009, 64:1274-1281.
51. Herbrecht R., Maertens J., Baila L., Aoun M., Heinz W., Martino R., Schwartz S., Ullmann A.J., zMeert L., Paesmans M., et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients: an European Organisation for Research and Treatment of Cancer Study. Bone Marrow Transplant 2010, 1-7.
52. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O., Kauffman, et al. Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
53. Segal B.H., Herbrecht R., Stevens D.A., Ostrosky-Zeichner L., Sobel J., Vsicoli C., Walsh T.J., Maertens J., Patterson T.F., Perfect J.R., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organisation for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
54. Zaoutis T., Jafri H.S., Huang L.-M., Locatelli F., Barzalai A., Ebell W., Steinbach W., Bradley J., Lieberman J.M., Hsiao C.-C., et al. A prospective multicentre study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009, 123:877-884.
55. Caillot D., Thiebaut T.A., Herbrecht R., Botton S., Pigneux A., Bernard F., Larche J., Monchecourt F., Alfandari S., Mahi L. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (COMBISTRAT trial). Cancer 2007, 110:2740-2746.
56. Alastruey-Izuquierdo A., Caselli M.V., Cuesta I., Monzon A., Cuenca-Estrella M., Rodriguez-Tudela J.L. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother 2009, 53:1686-1689.
57. Sun Q.N., Navjar L.K., Bocanegra R., Loebenberg D., Graybill J.R. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002, 46:2310-2312.
58. Spellberg B., Walsh T.J., Kontoyiannis D.P., Edwards J.E., Ibrahim A.S. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009, 48:1743-1751.
59. Singh N., Aguado J.M., Bonatti H., Forrest G., Gupta K.L., Safdar N., John G.T., Pursell K., Munoz P., Patel R., et al. Zygomycosis in solid organ transplant recipients: a prospective matched case-control study to assess risks for disease and outcome. J Infect Dis 2009, 200:1002-1011.
60. Reed C., Bryant R., Ibrahim A., Edwards J., Filler S.G., Goldberg R., Spellbertg B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
61. Krishna G., Martinho M., Chandrasekar P., Ullmann A.J., Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoeitic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007, 27:16127-21636.
62. Greenberg R.N., Mullane K., Van Burik J.A., Raad I., Abzug M.J., Anstead G., Herbrecht R., Langston A., Marr K.A., Schiller G., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
63. Ibrahim A.S., Gebremariam T., Schwartz J., Edwards J.E., Spellberg B. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009, 53:772-775.
64. Ben-Ami R., Lewis R.E., Tarrand J., Leventakos K., Kontoyiannis D.P. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 2010, 54:484-490.
65. Gilgado F., Serena C., Cano J., Gene J., Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006, 50:4211-4213.
66. Troke P., Aguirrebengoa K., Arteaga C., Ellis D., Heath C., Lutsar I., Rovira M., Nguyen Q., Slavin M., Chen S. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008, 52:1743-1750.
67. Cortez K.J., Roilides E., Quiroz-Telles F., Meletiadis J., Antachopoulos C., Knudsen T., Buchanan W., Milanovich J., Sutton D.A., Fothergill A., et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008, 21:157-197.
68. Heath C., Slavin M., Sorrell T.C., Handke R., Harun A., Philips M., Nguyen Q., Delhaes L., Ellis D., Meyer W., Chen S.C.A. Population-based surveillance for Scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009, 15:689-693.
69. Cuenca-Estrella M., Alastruey-Izquierdo A., Alcazar-Fuoli L., Bernal-Martinez L., Gomez-Lopez A., Buitrago M.J., Mellado E., Rodriguez-Tudela J.L. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother 2008, 52:1136-1139.
70. Kesson A.M., Bellemore M.C., O'Mara T.J., Ellis D.H., Sorrell T.C. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009, 48:1257-1261.
71. Alastruey-Izquierdo A., CuencaEestella M., Monzon A., Mellado E., Rodriguez-Tudela J.L. Antifungal susceptibility profile of clinical Fusarium spp. isolates. J Antimicrob Chemother 2008, 61:805-809.
72. Nucci M., Anaissie E. Fusarium infections in immunocompromsied patients. Clin Microbiol Rev 2007, 30:695-704.
73. Stanzani M., Tumietoo F., Vianelli N., Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manage 2007, 3:1165-1173.
74. Klont R.R., Eggink C.A., Rijs A., Wesseling P., Verwiej P.E. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005, 40:e110-112.
75. Scott L.J., Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007, 67:269-278.
76. Tu E.Y., McCartney D.L., Beatty R.E., Springer K., Levy J., Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007, 143:222-227.
77. Perkhofer S., Lechner V., Lass-florl C. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009, 53:1645-1647.
78. Ibrahim A.S., Spellberg B., Edwards J.E. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 2008, 21:620-625.
79. Reed C., Ibrahim A., Edwards J.E., Walot I., Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968-3969.
80. Ibrahim A.S., Gebremariam T., French S.W., Edwards J.E., Spellberg B. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Antimicrob Chemother 2010, 65:289-292.
81. Ibrahim A.S., Gebremariam T., Fu Y., Lin L., Husseiny M., French S.W., Schawrz J., Skory C.D., Edwards J.E., Spellberg B. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649-2657.